- Home
- LEXX vs TENX Comparison
LEXX vs TENX Comparison
Compare LEXX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- TENX
- Stock Information
- Founded
- LEXX 2004
- TENX 1967
- Country
- LEXX Canada
- TENX United States
- Employees
- LEXX N/A
- TENX N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- TENX Health Care
- Exchange
- LEXX Nasdaq
- TENX Nasdaq
- Market Cap
- LEXX 19.6M
- TENX 21.6M
- IPO Year
- LEXX N/A
- TENX N/A
- Fundamental
- Price
- LEXX $0.89
- TENX $5.78
- Analyst Decision
- LEXX Strong Buy
- TENX Strong Buy
- Analyst Count
- LEXX 1
- TENX 3
- Target Price
- LEXX $5.00
- TENX $16.00
- AVG Volume (30 Days)
- LEXX 146.9K
- TENX 41.0K
- Earning Date
- LEXX 07-22-2025
- TENX 08-12-2025
- Dividend Yield
- LEXX N/A
- TENX N/A
- EPS Growth
- LEXX N/A
- TENX N/A
- EPS
- LEXX N/A
- TENX N/A
- Revenue
- LEXX $525,923.00
- TENX N/A
- Revenue This Year
- LEXX $0.62
- TENX N/A
- Revenue Next Year
- LEXX $14.19
- TENX N/A
- P/E Ratio
- LEXX N/A
- TENX N/A
- Revenue Growth
- LEXX 29.95
- TENX N/A
- 52 Week Low
- LEXX $0.82
- TENX $2.80
- 52 Week High
- LEXX $4.38
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- LEXX 41.23
- TENX 48.62
- Support Level
- LEXX $0.86
- TENX $5.68
- Resistance Level
- LEXX $1.05
- TENX $5.98
- Average True Range (ATR)
- LEXX 0.06
- TENX 0.48
- MACD
- LEXX 0.00
- TENX -0.01
- Stochastic Oscillator
- LEXX 30.70
- TENX 31.38
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.